Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.
Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.
John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the right patients for these procedures.
